Noven Pharmaceuticals (NOVN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Noven Pharmaceuticals (NOVN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Todd D. Wiener who wrote ()	10/8/1997 12:48:00 PM
From: Todd D. Wiener	of 66

Noven Pharmaceuticals Files Two INDs with FDA Business Wire - October 08, 1997 07:59 MIAMI--(BUSINESS WIRE)--Oct. 8, 1997-- Clinical Trials to Begin for Transoral and Transdermal Patches Before Year End Noven Pharmaceuticals Inc. (NASDAQ:NOVN) announced Wednesday the filing of Investigational New Drug Applications (INDs) with the FDA to begin human clinical trials for two new drug delivery systems. These studies are expected to begin before the end of 1997. Noven will evaluate a novel transoral patch containing ketoprofen for the site specific treatment of post operative dental pain. Ketoprofen is a widely used non steroidal anti-inflammatory drug (NSAID) typically given as tablets or capsules. In addition, clinical trials are expected to begin shortly for a new scopolamine transdermal drug delivery system for the prevention of motion sickness. Noven Pharmaceuticals Inc. is an industry leader in the development and commercialization of advanced drug delivery systems.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next